Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2025)
Historic Total Current Liabilities for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $24.1 million.
- Keros Therapeutics' Total Current Liabilities fell 1694.42% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year decrease of 1694.42%. This contributed to the annual value of $27.4 million for FY2024, which is 1262.46% up from last year.
- Latest data reveals that Keros Therapeutics reported Total Current Liabilities of $24.1 million as of Q3 2025, which was down 1694.42% from $34.7 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Total Current Liabilities registered a high of $39.4 million during Q1 2025, and its lowest value of $7.5 million during Q2 2021.
- Over the past 5 years, Keros Therapeutics' median Total Current Liabilities value was $16.5 million (recorded in 2022), while the average stood at $19.0 million.
- Over the last 5 years, Keros Therapeutics' Total Current Liabilities had its largest YoY gain of 11038.04% in 2025, and its largest YoY loss of 1694.42% in 2025.
- Over the past 5 years, Keros Therapeutics' Total Current Liabilities (Quarter) stood at $11.8 million in 2021, then skyrocketed by 39.68% to $16.5 million in 2022, then surged by 47.3% to $24.4 million in 2023, then grew by 12.62% to $27.4 million in 2024, then fell by 12.23% to $24.1 million in 2025.
- Its Total Current Liabilities was $24.1 million in Q3 2025, compared to $34.7 million in Q2 2025 and $39.4 million in Q1 2025.